Predictors of long-term survival in patients with glioblastoma multiforme: Advancements from the last quarter century

Cancer Investigation

Volumn 31, Issue 5, 2013, Pages 287-308

  Chaudhry, Nauman S ^a   Shah, Ashish H ^a   Ferraro, Nicholas ^a   Snelling, Brian M ^a   Bregy, Amade ^a   Madhavan, Karthik ^a   Komotar, Ricardo J ^a  

^a UNIVERSITY OF MIAMI HOSPITAL   (United States)

Author keywords

Brain tumors; Cancer biomarkers; CNS malignancy; Glioblastoma multiforme; Prognosis and response; Systematic analysis; Treatment

Indexed keywords

AGE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DNA METHYLATION; GENE MUTATION; GLIOBLASTOMA; HUMAN; LONG TERM SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; SURVIVORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877960698     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2013.789899     Document Type: Review

References (142)

1. Bruce J, Benjamin K. Glioblastoma multiforme: Medscape Reference, 2011.
2. Tugcu B, Postalci LS, Gunaldi O, Tanriverdi O, Akdemir H. Ef-fcacy of clinical prognostic factors on survival in patients with glioblastoma. Turk Neurosurg 2010;20(2):117-125.
3. Azizi A, Black P, Miyamoto C, Croul SE. Treatment of malignant astrocytomas with repetitive resections: a longitudinal study. Isr Med Assoc J 2001;3(4):254-257. (Pubitemid 32447480)
4. Donato V, Papaleo A, Castrichino A, Banelli E, Giangaspero F, Salvati M, Delfni R. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori 2007;93(3):248-256. (Pubitemid 47080010)
5. Ma X, Lv Y, Liu J, Wang D, Huang Q, Wang X, Li G, Xu S, Li X. Survival analysis of 205 patients with glioblastoma multiforme: clinical characteristics, treatment and prognosis in China. J Clin Neurosci 2009;16(12):1595-1598.
6. Paravati AJ, Heron DE, Landsittel D, Flickinger JC, Mintz A, Chen YF, Huq MS. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Terapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. J Neurooncol 2011;104(1):339-349.
7. Cofey RJ, Lunsford LD, Taylor FH. Survival afer stereotactic biopsy of malignant gliomas. Neurosurgery 1988;22(3):465-473. (Pubitemid 18095947)
8. Allahdini F, Amirjamshidi A, Reza-Zarei M, Abdollahi M. Evaluating the prognostic factors efective on the outcome of patients with glioblastoma multiformis: does maximal resection of the tumor lengthen the median survival? World Neurosurg 2010;73(2):128-134; discussion e16.
9. Young GS, Macklin EA, Setayesh K, Lawson JD, Wen PY, Nor-den AD, Drappatz J, Kesari S. Longitudinal MRI evidence for decreased survival among periventricular glioblastoma. J Neu-rooncol 2011;104(1):261-269.
10. Polin RS, Marko NF, Ammerman MD, Shafrey ME, Huang W, Anderson FA, Jr., Caputy AJ, Laws ER. Functional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheres. J Neurosurg 2005;102(2):276-283. (Pubitemid 43194077)
11. Silbergeld DL, Rostomily RC, Alvord EC, Jr. The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy fndings in 117 cases of supratentorial glioblastoma in adults. J Neurooncol 1991;10(2):179-185.
12. Kowalczuk A, Macdonald RL, Amidei C, Dohrmann G, 3rd, Er-ickson RK, Hekmatpanah J, Krauss S, Krishnasamy S, Masters G, Mullan SF, Mundt AJ, Sweeney P, Vokes EE, Weir BK, Woll-man RL. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 1997;41(5):1028-1036; discussion 36-38.
13. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95(2):190-198. (Pubitemid 32799739)
14. Jakola AS, Gulati S, Weber C, Unsgard G, Solheim O. Postoperative deterioration in health related quality of life as predictor for survival in patients with glioblastoma: a prospective study. PLoS One 2011;6(12):e28592.
15. Tang V, Rathbone M, Park Dorsay J, Jiang S, Harvey D. Rehabilitation in primary and metastatic brain tumours: impact of functional outcomes on survival. J Neurol 2008;255(6):820-827.
16. Jacinto FV, Esteller M. MGMT hypermethylation: a prognostic foe, a predictive friend. DNA Repair (Amst) 2007;6(8):1155-1160. (Pubitemid 47058396)
17. Mason WP, Cairncross JG. Drug insight: temozolomide as a treatment for malignant glioma-impact of a recent trial. Nat Clin Pract Neurol 2005;1(2):88-95.
18. Weller M, Steinbach JP, Wick W. Temozolomide: a milestone in the pharmacotherapy of brain tumors. Future Oncol 2005;1(6):747-754.
19. Kitange GJ, Carlson BL, Schroeder MA, Decker PA, Morlan BW, Wu W, Ballman KV, Giannini C, Sarkaria JN. Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. J Neurooncol 2010;100(2):177-186.
20. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hain-fellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008;26(18):3015- 3024.
21. Masoudi A, Elopre M, Amini E, Nagel ME, Ater JL, Gopalakrishnan V, Wolf JE. Infuence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 2008;28(4C):2437-2442.
22. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Six-month progression-free survival as an alternative primary efcacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol 2010;12(3):274-282.
23. Marina O, Suh JH, Reddy CA, Barnett GH, Vogelbaum MA, Peereboom DM, Stevens GH, Elinzano H, Chao ST. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article. J Neurosurg 2011;115(2):220-229.
24. Karacetin D, Okten B, Yalcin B, Incekara O. Concomitant temo-zolomide and radiotherapy versus radiotherapy alone for treatment of newly diagnosed glioblastoma multiforme. J BUON 2011;16(1):133-137.
25. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanof RO. Efects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10(5):459-466.
26. Watanabe T, Katayama Y, Yoshino A, Fukaya C, Yamamoto T. Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocy-tomas. J Neurooncol 2005;72(1):57-62. (Pubitemid 41149178)
27. Jubelirer SJ. A review of the treatment and survival rates of 138 patients with glioblastoma multiforme. W V Med J 1996;92(4):186-190.
28. Barker FG, 2nd, Prados MD, Chang SM, Gutin PH, Lamborn KR, Larson DA, Malec MK, McDermott MW, Sneed PK, Wara WM, Wilson CB. Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg 1996;84(3):442-448. (Pubitemid 26062869)
29. Sarkaria JN, Mehta MP, Loefer JS, Buatti JM, Chappell RJ, Levin AB, Alexander E, 3rd., Friedman WA, Kinsella TJ. Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Radiation Terapy Oncology Group. Int J Radiat Oncol Biol Phys 1995;32(4):931-941.
30. Miller PJ, Hassanein RS, Giri PG, Kimler BF, O'Boynick P, Evans RG. Univariate and multivariate statistical analysis of high-grade gliomas: the relationship of radiation dose and other prognostic factors. Int J Radiat Oncol Biol Phys 1990;19(2):275-280. (Pubitemid 20299018)
31. Nwokedi EC, DiBiase SJ, Jabbour S, Herman J, Amin P, Chin LS. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery 2002;50(1):41-6; discussion 46-47. (Pubitemid 41672553)
32. Showalter TN, Andrel J, Andrews DW, Curran WJ, Jr, Daskalakis C, Werner-Wasik M. Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys 2007;69(3):820-824. (Pubitemid 47418387)
33. Shih HA, Betensky RA, Dorfman MV, Louis DN, Loefer JS, Batchelor TT. Genetic analyses for predictors of radiation response in glioblastoma. Int J Radiat Oncol Biol Phys 2005;63(3):704-710. (Pubitemid 41400055)
34. Wang Y, Pantelias GE, Iliakis G. Mechanism of radiosensitization by halogenated pyrimidines: the contribution of excess DNA and chromosome damage in BrdU radiosensitization may be minimal in plateau-phase cells. Int J Radiat Biol 1994;66(2):133-142. (Pubitemid 24285377)
35. Kinsella TJ, Collins J, Rowland J, Klecker R, Jr., Wright D, Katz D, Steinberg SM, Glastein E. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hy-perfractionated radiotherapy in patients with glioblastoma mul-tiforme. J Clin Oncol 1988;6(5):871-879.
36. Urtasun RC, Cosmatos D, DelRowe J, Kinsella TJ, Lester S, Wasserman T, Fulton DS. Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: a comparison of short versus long intravenous dose schedules (RTOG 86-12). Int J Radiat Oncol Biol Phys 1993;27(2):207-214. (Pubitemid 23304444)
37. Hoshino T, Ahn D, Prados MD, Lamborn K, Wilson CB. Prognostic signifcance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling. Int J Cancer 1993;53(4):550-555. (Pubitemid 23069262)
38. Fazeny-Dorner B, Wenzel C, Veitl M, Piribauer M, Rossler K, Dieckmann K, Ungersbock K, Marosi C. Survival and prognostic factors of patients with unresectable glioblastoma multiforme. Anticancer Drugs 2003;14(4):305-312. (Pubitemid 36583816)
39. Blumenthal DT, Won M, Mehta MP, Curran WJ, Souhami L, Michalski JM, Rogers CL, Corn BW. Short delay in initiation of radiotherapy may not afect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. J Clin Oncol 2009;27(5):733-739.
40. Barnholtz-Sloan JS, Williams VL, Maldonado JL, Shahani D, Stockwell HG, Chamberlain M, Sloan AE. Patterns of care and outcomes among elderly individuals with primary malignant as-trocytoma. J Neurosurg 2008;108(4):642-648. (Pubitemid 351498955)
41. Barker FG, 2nd, Chang SM, Larson DA, Sneed PK, Wara WM, Wilson CB, Prados MD. Age and radiation response in glioblas-toma multiforme. Neurosurgery 2001;49(6):1288-1297; discussion 97-8.
42. Mohan DS, Suh JH, Phan JL, Kupelian PA, Cohen BH, Barnett GH. Outcome in elderly patients undergoing defnitive surgery and radiation therapy for supratentorial glioblastoma multi-forme at a tertiary care institution. Int J Radiat Oncol Biol Phys 1998;42(5):981-987. (Pubitemid 29004138)
43. Ewelt C, Goeppert M, Rapp M, Steiger HJ, Stummer W, Sabel M. Glioblastoma multiforme of the elderly: the prognostic efect of resection on survival. J Neurooncol 2011;103(3):611-618.
44. Iwamoto FM, Cooper AR, Reiner AS, Nayak L, Abrey LE. Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997-2007). Cancer 2009;115(16):3758-3766.
45. Chaichana KL, Chaichana KK, Olivi A, Weingart JD, Bennett R, Brem H, Quinones-Hinojosa A. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
46. Kleinschmidt-DeMasters BK, Lillehei KO, Varella-Garcia M. Glioblastomas in the older old. Arch Pathol Lab Med 2005;129(5):624-631. (Pubitemid 40616965)
47. Veilleux N, Gofaux P, Boudrias M, Mathieu D, Daigle K, Fortin D. Quality of life in neurooncology-age matters. J Neurosurg 2010;113(2):325-332.
48. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 2000;18(3):646-650. (Pubitemid 30078546)
49. Muacevic A, Kreth FW. Quality-adjusted survival afer tumor resection and/or radiation therapy for elderly patients with glioblastoma multiforme. J Neurol 2003;250(5):561-568. (Pubitemid 36613299)
50. Garcia-Navarrete R, Garcia E, Arrieta O, Sotelo J. Hepatocyte growth factor in cerebrospinal fuid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. J Neurooncol 2010;97(3):347-351.
51. Ljubimova JY, Fugita M, Khazenzon NM, Das A, Pikul BB, Newman D, Sekiguchi K, Sorokin LM, Sasaki T, Black KL. Association between laminin-8 and glial tumor grade, recurrence, and patient survival. Cancer 2004;101(3):604-612. (Pubitemid 38970612)
52. Brown WD, Tavare CJ, Sobel EL, Gilles FH. The applicability of Collins' Law to childhood brain tumors and its usefulness as a predictor of survival. Neurosurgery 1995;36(6):1093-1096.
53. Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schif D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13(1):143-151.
54. Combs SE, Tilmann C, Edler L, Debus J, Schulz-Ertner D. Efcacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 2005;23(34):8863-8869. (Pubitemid 46211533)
55. Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R. Hypofractionated stereotactic reirra-diation of recurrent glioblastomas: a benefcial treatment option afer high-dose radiotherapy? Strahlenther Onkol 2009;185(4):235-240.
56. Rusthoven KE, Olsen C, Franklin W, Kleinschmidt-DeMasters BK, Kavanagh BD, Gaspar LE, Lillehei K, Waziri A, Damek DM, Chen C. Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series. Int J Radiat Oncol Biol Phys 2011;81(1):211-217.
57. Montano N, D'Alessandris QG, Bianchi F, Lauretti L, Doglietto F, Fernandez E, Maira G, Pallini R. Communicating hydrocephalus following surgery and adjuvant radiochemotherapy for glioblas-toma. J Neurosurg 2011;115(6):1126-1130.
58. Bernstein M, Laperriere N, Leung P, McKenzie S. Interstitial brachytherapy for malignant brain tumors: preliminary results. Neurosurgery 1990;26(3):371-379; discussion 79-80.
59. Mayr MT, Crocker IR, Butker EK, Williams H, Cotsonis GA, Olson JJ. Results of interstitial brachytherapy for malignant brain tumors. Int J Oncol 2002;21(4):817-823.
60. Simon JM, Cornu P, Boisserie G, Hasboun D, Tep B, Hardiman C, Valery CA, Delattre JY, Dormont D, Baillet F, Mazeron JJ. Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys 2002;53(1):67-74. (Pubitemid 34467054)
61. Keles GE, Lamborn KR, Chang SM, Prados MD, Berger MS. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 2004;100(1):41-46. (Pubitemid 38017813)
62. Leibel SA, Gutin PH, Wara WM, Silver PS, Larson DA, Edwards MS, Lamb SA, Ham B, Weaver KA, Barnett C, et al. Survival and quality of life afer interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 1989;17(6):1129-1139. (Pubitemid 20028628)
63. Hilverda K, Bosma I, Heimans JJ, Postma TJ, Peter Vandertop W, Slotman BJ, Buter J, Reijneveld JC, Klein M. Cognitive functioning in glioblastoma patients during radiotherapy and temozolo-mide treatment: initial fndings. J Neurooncol 2010;97(1):89-94.
64. Corn BW, Wang M, Fox S, Michalski J, Purdy J, Simpson J, Kresl J, Curran WJ, Jr., Diaz A, Mehta M, Movsas B. Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of confor-mal three dimensional radiation on RTOG 98-03. J Neurooncol 2009;95(2):247-257.
65. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Clough-esy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 2005;26(10):2466-2474.
66. Cao Y, Tsien CI, Nagesh V, Junck L, Ten Haken R, Ross BD, Chenevert TL, Lawrence TS. Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys 2006;64(3):876-885. (Pubitemid 43183588)
67. Mangla R, Singh G, Ziegelitz D, Milano MT, Korones DN, Zhong J, Ekholm SE. Changes in relative cerebral blood volume 1 month afer radiation- temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 2010;256(2):575-584.
68. Blankenberg FG, Teplitz RL, Ellis W, Salamat MS, Min BH, Hall L, Boothroyd DB, Johnstone IM, Enzmann DR. The infuence of volumetric tumor doubling time, DNA ploidy, and histologic grade on the survival of patients with intracranial astrocytomas. AJNR Am J Neuroradiol 1995;16(5):1001-1012.
69. Kaur G, Bloch O, Jian BJ, Kaur R, Sughrue ME, Aghi MK, Mc-Dermott MW, Berger MS, Chang SM, Parsa AT. A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival. J Neurosurg 2011;115(4):754-759.
70. Saksena S, Jain R, Narang J, Scarpace L, Schultz LR, Lehman NL, Hearshen D, Patel SC, Mikkelsen T. Predicting survival in glioblastomas using difusion tensor imaging metrics. J Magn Reson Imaging 2010;32(4):788-795.
71. Kim S, Chung JK, Im SH, Jeong JM, Lee DS, Kim DG, Jung HW, Lee MC. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2005;32(1):52-59. (Pubitemid 40142778)
72. Vos MJ, Berkhof J, Hoekstra OS, Bosma I, Sizoo EM, Heimans JJ, Reijneveld JC, Sanchez E, Lagerwaard FJ, Buter J, Noske DP, Postma TJ. MRI and thallium-201 SPECT in the prediction of survival in glioma. Neuroradiology 2012;54(6):539-546.
73. Essock-Burns E, Lupo JM, Cha S, Polley MY, Butowski NA, Chang SM, Nelson SJ. Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 2011;13(1):119-131.
74. Cao Y, Nagesh V, Hamstra D, Tsien CI, Ross BD, Chenevert TL, Junck L, Lawrence TS. The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res 2006;66(17):8912-8917. (Pubitemid 44449210)
75. Datta NR, Pasricha R, Gambhir S, Phadke RV, Prasad SN. Postoperative residual tumour imaged by contrast-enhanced computed tomography and 201Tl single photon emission tomography: can they predict progression-free survival in high-grade gliomas? Clin Oncol (R Coll Radiol) 2004;16(7):494-500. (Pubitemid 39232949)
76. Grant R, Walker M, Hadley D, Barton T, Osborn C. Imaging response to chemotherapy with RMP-7 and carboplatin in malignant glioma: size matters but speed does not. J Neurooncol 2002;57(3):241-245. (Pubitemid 34692632)
77. Furneaux CE, Marshall ES, Yeoh K, Monteith SJ, Mews PJ, Sansur CA, Oskouian RJ, Sharples KJ, Baguley BC. Cell cycle times of short-term cultures of brain cancers as predictors of survival. Br J Cancer 2008;99(10):1678-1683.
78. Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM, Lazaref JA, Mis-chel PS, Cloughesy TF, Horvath S, Kornblum HI. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells 2009;27(4):980-987.
79. Hoke M, Dieckmann K, Koppensteiner R, Schillinger M, Marosi C, Mlekusch W. Prognostic value of plasma d-dimer levels in patients with glioblastoma multiforme-Results from a pilot study. Wien Klin Wochenschr 2011;123(7-8):199- 203.
80. Brockmann MA, Giese A, Mueller K, Kaba FJ, Lohr F, Weiss C, Gottschalk S, Nolte I, Leppert J, Tuettenberg J, Groden C. Pre-operative thrombocytosis predicts poor survival in patients with glioblastoma. Neuro Oncol 2007;9(3):335-342. (Pubitemid 47169666)
81. Borg N, Guilfoyle MR, Greenberg DC, Watts C, Tomson S. Serum albumin and survival in glioblastoma multiforme. J Neu-rooncol 2011;105(1):77-81.
82. Crocker M, Ashley S, Giddings I, Petrik V, Hardcastle A, Ah-erne W, Pearson A, Bell BA, Zacharoulis S, Papadopoulos MC. Serum angiogenic profle of patients with glioblastoma identifes distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro Oncol 2011;13(1):99-108.
83. Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins RB, Al-dape KD. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 2005;11(9):3326-3334. (Pubitemid 40627883)
84. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 2006;12(19):5698-5704. (Pubitemid 44629598)
85. Strojnik T, Kos J, Zidanik B, Golouh R, Lah T. Cathepsin B im-munohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin Cancer Res 1999;5(3):559-567. (Pubitemid 29131965)
86. Fukuda ME, Iwadate Y, Machida T, Hiwasa T, Nimura Y, Nagai Y, Takiguchi M, Tanzawa H, Yamaura A, Seki N. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res 2005;65(12):5190-5194. (Pubitemid 40827328)
87. Flannery T, McQuaid S, McGoohan C, McConnell RS, McGregor G, Mirakhur M, Hamilton P, Diamond J, Cran G, Walker B, Scott C, Martin L, Ellison D, Patel C, Nicholson C, Mendelow D, McCormick D, Johnston PG. Cathepsin S expression: An independent prognostic factor in glioblastoma tumours-a pilot study. Int J Cancer 2006;119(4):854-860. (Pubitemid 44051449)
88. Peles E, Lidar Z, Simon AJ, Grossman R, Nass D, Ram Z. An-giogenic factors in the cerebrospinal fuid of patients with astro-cytic brain tumors. Neurosurgery 2004;55(3):562-567; discussion 67-8. (Pubitemid 39186844)
89. Fukui S, Nawashiro H, Otani N, Ooigawa H, Nomura N, Yano A, Miyazawa T, Ohnuki A, Tsuzuki N, Katoh H, Ishihara S, Shima K. Nuclear accumulation of basic fbroblast growth factor in human astrocytic tumors. Cancer 2003;97(12):3061- 3067. (Pubitemid 36676261)
90. Colin C, Voutsinos-Porche B, Nanni I, Fina F, Metellus P, Intagli-ata D, Baeza N, Bouvier C, Delfno C, Loundou A, Chinot O, Lah T, Kos J, Martin PM, Ouafk L, Figarella-Branger D. High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathol 2009;118(6):745-754.
91. Petrik V, Saadoun S, Loosemore A, Hobbs J, Opstad KS, Sheldon J, Tarelli E, Howe FA, Bell BA, Papadopoulos MC. Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem 2008;54(4):713-722. (Pubitemid 351573704)
92. McKeever PE, Feldenzer JA, McCoy JP, Laug M, Gebarski S, Chandler WF, Greenberg HS, Junck L, D'Amato CJ, Varani J. Nuclear parameters as prognostic indicators in glioblastoma patients. J Neuropathol Exp Neurol 1990;49(1):71-78. (Pubitemid 20056745)
93. Srinivasan S, Patric IR, Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One 2011;6(3):e17438.
94. Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, et al. MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic signifcance. Clin Cancer Res 2010;16(16):4289-4297.
95. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al. A multigene predictor of outcome in glioblas-toma. Neuro Oncol 2010;12(1):49-57.
96. Sato A, Sakurada K, Kumabe T, Sasajima T, Beppu T, Asano K, et al. Association of stem cell marker CD133 expression with dissemination of glioblastomas. Neurosurg Rev 2010;33(2):175-183; discussion 83-84.
97. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN. Gene expression-based classifcation of malignant gliomas correlates better with survival than histological classifcation. Cancer Res 2003;63(7):1602-1607. (Pubitemid 36373650)
98. Ducray F, Idbaih A, Wang XW, Cheneau C, Labussiere M, San-son M. Predictive and prognostic factors for gliomas. Expert Rev Anticancer Ter 2011;11(5):781-789.
99. Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, Tillet J, Delattre JY, Hoang-Xuan K, Sanson M. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006;106(10):2218-2223. (Pubitemid 43673244)
100. Rasheed A, Herndon JE, Stenzel TT, Raetz JG, Kendelhardt J, Friedman HS, Friedman AH, Bigner DD, Bigner SH, McLendon RE. Molecular markers of prognosis in astrocytic tumors. Cancer 2002;94(10):2688-2697. (Pubitemid 34478085)
101. Hung KS, Howng SL. Prognostic signifcance of annexin VII expression in glioblastomas multiforme in humans. J Neurosurg 2003;99(5):886-892.
102. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB. PTEN mutation, EGFR amplifcation, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001;93(16):1246- 1256. (Pubitemid 32816199)
103. Umesh S, Tandon A, Santosh V, Anandh B, Sampath S, Chan-dramouli BA, Sastry Kolluri VR. Clinical and immunohisto-chemical prognostic factors in adult glioblastoma patients. Clin Neuropathol 2009;28(5):362-372.
104. Wemmert S, Bettscheider M, Alt S, Ketter R, Kammers K, Fei-den W, Steudel WI, Rahnenfuhrer J, Urbschat S. p15 promoter methylation-a novel prognostic marker in glioblastoma patients. Int J Oncol 2009;34(6):1743-1748.
105. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifen-berger G, von Deimling A, Loefer M. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009;27(34):5743-5750.
106. Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M, Yarosh DB, Bearman SI, Giroux DJ, Schold SC. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998;16(10):3310-3315. (Pubitemid 28481626)
107. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Os-termann S, Otten P, Van Melle G, de Tribolet N, Stupp R. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10(6):1871-1874. (Pubitemid 38375541)
108. Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, Steinbach JP, Hundsberger T, Wick W, Meyermann R, Tan TC, Sommer C, Bamberg M, Reifenberger G, Weller M. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006;24(27):4412-4417. (Pubitemid 46630979)
109. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD. MGMT promoter methy-lation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblas-toma. Neuro Oncol 2010;12(2):116-121.
110. Uno M, Oba-Shinjo SM, Camargo AA, Moura RP, Aguiar PH, Cabrera HN, Begnami M, Rosemberg S, Teixeira MJ, Marie SK. Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma. Clinics (Sao Paulo) 2011;66(10):1747-1755.
111. Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS One 2011;6(8):e23332.
112. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009;15(19):6002-6007.
113. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60(5):1383-1387. (Pubitemid 30152011)
114. Zhu A, Shaefer J, Leslie S, Kolm P, El-Mahdi AM. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given defnitive irradiation. Int J Radiat Oncol Biol Phys 1996;34(4):809-815. (Pubitemid 26089218)
115. Etienne MC, Formento JL, Lebrun-Frenay C, Gioanni J, Cha-tel M, Paquis P, Bernard C, Courdi A, Bensadoun RJ, Pig-nol JP, Francoual M, Grellier P, Frenay M, Milano G. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 1998;4(10):2383- 2390. (Pubitemid 28477903)
116. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y, Ushio Y. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63(20):6962-6970. (Pubitemid 37322983)
117. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K. Prognostic efect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005;11(4):1462-1466. (Pubitemid 40315227)
118. Potti A, Forseen SE, Koka VK, Pervez H, Koch M, Fraiman G, Mehdi SA, Levitt R. Determination of HER-2/neu overex-pression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. Cancer Invest 2004;22(4):537-544. (Pubitemid 39506874)
119. Stark AM, Hugo HH, Witzel P, Mihajlovic Z, Mehdorn HM. Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblas-toma multiforme. Zentralbl Neurochir 2003;64(1):30-36. (Pubitemid 36176306)
120. Tchirkov A, Rolhion C, Kemeny JL, Irthum B, Puget S, Khalil T, Chinot O, Kwiatkowski F, Perissel B, Vago P, Verrelle P. Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Br J Cancer 2003;88(4):516-520. (Pubitemid 36363360)
121. Boldrini L, Pistolesi S, Gisfredi S, Ursino S, Ali G, Pier-acci N, Basolo F, Parenti G, Fontanini G. Telomerase activity and hTERT mRNA expression in glial tumors. Int J Oncol 2006;28(6):1555-1560.
122. Wang L, Wei Q, Wang LE, Aldape KD, Cao Y, Okcu MF, Hess KR, El-Zein R, Gilbert MR, Woo SY, Prabhu SS, Fuller GN, Bondy ML. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol 2006;24(10):1627-1632. (Pubitemid 46638787)
123. Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO. Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatry 1995;59(4):413-419.
124. Kyritsis AP, Bondy ML, Hess KR, Cunningham JE, Zhu D, Amos CJ, Yung WK, Levin VA, Bruner JM. Prognostic signifcance of p53 immunoreactivity in patients with glioma. Clin Cancer Res 1995;1(12):1617-1622. (Pubitemid 26028093)
125. Chozick BS, Pezzullo JC, Epstein MH, Finch PW. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 1994;35(5):831-837; discussion 37-38.
126. Arrieta O, Garcia E, Guevara P, Garcia-Navarrete R, Ondarza R, Rembao D, Sotelo J. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer 2002;94(12):3210-3218. (Pubitemid 34670504)
127. Wang XB, Tian XY, Li Y, Li B, Li Z. Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas. J Neu-rooncol 2012;106(1):43-51.
128. Kuan CT, Wakiya K, Herndon JE, 2nd, Lipp ES, Pegram CN, Rig-gins GJ, Rasheed A, Szafranski SE, McLendon RE, Wikstrand CJ, Bigner DD. MRP3: a molecular target for human glioblastoma multiforme immunotherapy. BMC Cancer 2010;10:468.
129. Santosh V, Arivazhagan A, Sreekanthreddy P, Srinivasan H, Tota B, Srividya MR, Vrinda M, Sridevi S, Shailaja BC, Samuel C, Prasanna KV, Tennarasu K, Balasubramaniam A, Chandramouli BA, Hegde AS, Somasundaram K, Kondaiah P, Rao MR. Grade-specifc expression of insulin-like growth factor-binding proteins-2,-3, and-5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma. Cancer Epidemiol Biomarkers Prev 2010;19(6):1399-1408.
130. Ali-Osman F, Brunner JM, Kutluk TM, Hess K. Prognostic sig-nifcance of glutathione S-transferase pi expression and subcel-lular localization in human gliomas. Clin Cancer Res 1997;3(12 Pt 1):2253-2261. (Pubitemid 28133143)
131. Liu Y, Shete S, Etzel CJ, Scheurer M, Alexiou G, Armstrong G, Tsavachidis S, Liang FW, Gilbert M, Aldape K, Armstrong T, Houlston R, Hosking F, Robertson L, Xiao Y, Wiencke J, Wrensch M, Andersson U, Melin BS, Bondy M. Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J Clin Oncol 2010;28(14):2467- 2474.
132. Kase M, Vardja M, Lipping A, Asser T, Jaal J. Impact of PARP-1 and DNA-PK expression on survival in patients with glioblastoma multiforme. Radiother Oncol 2011;101(1):127-131.
133. Sun B, Chu D, Li W, Chu X, Li Y, Wei D, Li H. Decreased expression of NDRG1 in glioma is related to tumor progression and survival of patients. J Neurooncol 2009;94(2):213-219.
134. Kuan CT, Wakiya K, Dowell JM, Herndon JE, 2nd, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD. Glycopro-tein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 2006;12(7 Pt 1):1970-1982.
135. Amoureux MC, Coulibaly B, Chinot O, Loundou A, Metellus P, Rougon G, Figarella-Branger D. Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. BMC Cancer 2010;10:91.
136. Chiba Y, Hashimoto N, Tsuboi A, Rabo C, Oka Y, Kinoshita M, Kagawa N, Oji Y, Sugiyama H, Yoshimine T. Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients. Brain Tumor Pathol 2010;27(1):29-34.
137. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, Ellsworth GB, Salzman KL, Kinney AY, Jensen RL. Hypoxia-regulated protein expression, patient characteristics, and preop-erative imaging as predictors of survival in adults with glioblas-toma multiforme. Cancer 2008;113(5):1032-1042.
138. Hofstetter CP, Burkhardt JK, Shin BJ, Gursel DB, Mubita L, Gor-repati R, Brennan C, Holland EC, Boockvar JA. Protein phos-phatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia. PLoS One 2012;7(1):e30059.
139. Shirai K, Suzuki Y, Oka K, Noda SE, Katoh H, Itoh J, Itoh H, Ishi-uchi S, Sakurai H, Hasegawa M, Nakano T. Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neuroon-col 2009;91(3):353-358.
140. Shono T, Toflon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic signifcance and molecular correlations. Cancer Res 2001;61(11):4375-4381. (Pubitemid 32685762)
141. American Cancer Society. Brain and Spinal Cord Tumors in Adults. Atlanta, Ga: American Cancer Society 2013.
142. Latif AZ, Signorini D, Gregor A, Grant R, Ironside JW, Whittle IR. Application of the MRC brain tumour prognostic index to patients with malignant glioma not managed in randomised control trial. J Neurol Neurosurg Psychiatry 1998;64(6):747-750. (Pubitemid 28274408)